Cancer prevalence in the UK is set to rise from 2 million in 2015 to 3.2 million by 2030. Metastases are the primary cause of mortality for many cancers.

Annually, 55,000 cases of bone cancer are diagnosed in the UK and of these 2/3rd patients will develop into metastatic bone disease

In the spine metastates can destroy bone in the vertebrae, weakening it and can cause significant spinal cord injury leading to paralysis.

A new concept in the treatment of bone metastases

OncoEng adopts a patient-centric methodology, forecasting vertebral failures due to tumors to guide treatment decisions.

We employ sophisticated computational modeling and imaging to predict vertebral integrity over time. Moreover, we’re developing minimally invasive, custom implants to reinforce at-risk vertebrae, minimising recovery time and discomfort.

Latest News

Exploring Metastatic Bone Disease Through Patient Narratives

As a mechanical engineer looking to develop methodologies to characterise spinal biomechanics and its perturbation due to metastatic bone disease (MBD), attending the OncoEng Patient Day was an eye-opening experience. This event provided an invaluable…

Birmingham Med-Tech Innovation Expo 2023

Blog written by Yash Karade and Aamena Lakdawala We bid farewell to Leeds on the morning of 7th June 2023 as we started our journey to the MedTech Expo in Birmingham. It was surely a…

National Patient Participation Week 31st May -6th June

PPG Awareness Week is an annual initiative aimed at raising awareness about the importance of Patient Participation Groups (PPGs) in healthcare. The event seeks to educate patients, the general public, and healthcare professionals about the…

World Cancer Day

The Leeds Cancer Research Centre will be delivering a mini-conference as part of World Cancer Day on the 3 rd February (World Cancer Day is actually on 4th Feb). OncoEng is very supportive of the…